Poseida Therapeutics’ (PSTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a report released on Friday,Benzinga reports. They currently have a $20.00 price target on the stock.

Poseida Therapeutics Stock Down 14.0 %

Shares of NASDAQ:PSTX opened at $2.76 on Friday. The company has a market capitalization of $268.99 million, a price-to-earnings ratio of -4.38 and a beta of 0.54. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 3.20. The business’s 50-day moving average is $2.81 and its 200-day moving average is $2.92. Poseida Therapeutics has a 1 year low of $1.87 and a 1 year high of $4.27.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PSTX. Vanguard Group Inc. raised its stake in Poseida Therapeutics by 16.3% during the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after buying an additional 473,746 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in Poseida Therapeutics by 89.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock worth $2,648,000 after buying an additional 391,801 shares during the period. Renaissance Technologies LLC raised its stake in Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after buying an additional 297,500 shares during the period. Blair William & Co. IL raised its stake in Poseida Therapeutics by 41.3% during the 1st quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock worth $3,079,000 after buying an additional 282,310 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in Poseida Therapeutics by 62.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock worth $1,027,000 after buying an additional 138,510 shares during the period. 46.87% of the stock is owned by institutional investors and hedge funds.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.